Table 3.

Antiviral activities of the test compounds against CMV in vivo.

Compound	Curative Activity (%) a	Protection Activity (%) a	Inactivation Activity (%) a
4a	29.3 ± 1.3	40.1 ± 2.5	71.3 ± 3.1
4b	23.6 ± 2.2	38.9 ± 2.9	65.2 ± 2.5
4c	37.9 ± 3.7	43.4 ± 3.1	61.5 ± 2.2
4d	18.5 ± 1.8	33.6 ± 2.1	51.2 ± 3.4
4e	55.9 ± 1.8	42.3 ± 1.1	79.6 ± 4.2
4f	50.2 ± 2.7	46.6 ± 2.3	62.5 ± 1.9
4g	39.8 ± 2.5	48.5 ± 2.7	66.7 ± 2.2
4h	39.8 ± 2.5	36.2 ± 2.2	62.1 ±1.9
4i	37.3 ± 2.5	35.6 ± 2.1	51.8 ± 1.1
4j	40.6 ± 3.7	45.9 ± 1.6	79.1± 2.5
4k	26.4 ± 2.3	35.6 ± 1.9	49.9± 3.6
4l	29.7 ± 1.1	43.5 ± 2.5	66.5 ± 2.0
4m	28.5 ± 2.3	42.2 ± 1.4	68.9 ± 2.8
4n	18.9 ± 2.9	25.4 ± 1.7	46.2 ± 0.9
4o	31.8 ± 2.8	49.9 ± 1.9	58.2 ± 3.2
4p	29.5 ± 1.4	38.5 ± 2.1	59.8 ± 1.9
4q	44.5 ± 1.8	48.1 ± 2.4	43.9 ± 1.2
4r	26.4 ± 2.2	40.5 ± 1.9	42.5 ± 2.8
4s	41.0 ± 1.7	54.7 ± 2.4	78.5 ± 1.9
4t	34.8 ± 2.3	48.1 ± 1.6	69.5 ± 2.0
Ribavirin b	36.8 ± 1.6	47.9 ± 2.7	71.2 ± 1.7

^a Average of three replicates, at 500 μg/mL. ^b A commercial antiviral agent.